Martine Zimmermann was appointed Director of Candel Therapeutics, Inc., effective September 8, 2026. As of November 6, 2026, Candel Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 10, 2026, naming 1 appointment (Form 8-K, September 10, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Candel Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Candel Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-10. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Candel Therapeutics, Inc. files it.
Also on the record for Candel Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 6.6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by RTW Investments, LP | 8.8% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.2% of the class | 5%+ stakes | Source |
| March 18, 2026 | Stake report, Schedule 13D/A, by Paul B Manning | 7.9% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Candel Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Candel Therapeutics, Inc. and the records around it.
Candel Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Jul 2026
- Who owns it
Companies that share a holder
- Paul B Manning also filed stake reports on 2 other companies: LIQUIDIA CORP (Aug 2026), Verrica Pharmaceuticals Inc. (Nov 2025)
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Candel Therapeutics, Inc.
Get an email when Candel Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Candel Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Candel Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Candel Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-10 | In | Director | 2026-09-08 | 8-K, 2026-09-10 |
Who leads Candel Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Martine Zimmermann, appointed, effective 2026-09-08 (filed 2026-09-10).
New leaders reset buying decisions — get the Full Report on Candel Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Candel Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Candel Therapeutics, Inc.Every change, in the filing's words
Appointed: Martine Zimmermann, Director, effective 2026-09-08
On September 6, 2026, the Board of Directors (the "Board") of Candel Therapeutics, Inc. (the "Company") increased the size of the Board from ten (10) to eleven (11) directors and unanimously appointed Martine Zimmermann, Pharm.D, to fill the newly created vacancy on the Board, effective September 8, 2026.
- Upon her appointment, Dr. Zimmermann became a member of the slate of Class III directors with terms expiring at the 2027 Annual Meeting of Stockholders of the Company.
- The Board has determined that Dr. Zimmermann qualifies as an independent director and is qualified to serve under the applicable rules and regulations of the Securities and Exchange Commission (the "SEC") and the listing rules of the Nasdaq Stock Market LLC.
- For her service on the Board, Dr. Zimmermann will receive an option to purchase 64,000 shares of the Company's common stock, vesting in equal monthly installments over three years.
- Dr. Zimmermann will also receive a $40,000 annual retainer for her service on the Board to be paid quarterly in arrears, pro-rated based on the number of actual days served by the director during such calendar quarter.
- Dr. Zimmermann has also entered into the Company's standard form of indemnification agreement.
- Dr. Zimmermann has served as the Executive Vice President of Regulatory Affairs and Quality Assurance of Inventiva S.A. since August 2025.
Tools for this story
Each opens in a new tab, filled in for Candel Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.